scispace - formally typeset
F

Filip K. Knop

Researcher at University of Copenhagen

Publications -  523
Citations -  17834

Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.

Papers
More filters
Journal ArticleDOI

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects

Nicolai Rhee, +5 more
- 01 Sep 2014 - 
TL;DR: These results suggest that acute increases in active incretin hormone levels do not affect glucose tolerance, GIGD, incret in effect, glucagon responses or gastric emptying in healthy subjects.
Journal ArticleDOI

Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity

Christina Nexøe-Larsen, +13 more
- 01 Nov 2018 - 
TL;DR: Treatment with liraglutide 3.0 mg has been associated with gallbladder‐related adverse events and a single‐centre, double‐blind, 12‐week trial comparing the effect of 0.6 mg liragsolutide and steady‐state lirAGlutides with placebo on gallbladders emptying in adults with body mass index (BMI) ≥27 kg/m2 and without diabetes is conducted.
Journal ArticleDOI

Effect of Exercise Combined With Glucagon-Like peptide-1 Receptor Agonist Treatment on Cardiac Function: A Randomized Double-Blind Placebo-Controlled Clinical Trial

Peter Godsk Jørgensen, +7 more
- 01 Jul 2017 - 
TL;DR: The addition of liraglutide to exercise in sedentary patients with dysregulated type 2 diabetes may blunt the suggested beneficial effect of exercise on LV diastolic function.
Journal ArticleDOI

Cardiovascular safety and benefits of GLP-1 receptor agonists

Niels B. Dalsgaard, +3 more
- 19 Jan 2017 - 
TL;DR: An overview of the existing GLP-1RAs with a particular focus on their clinical effects on CV risk factors and their CV safety and benefits is provided.
Journal ArticleDOI

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Sebastian M. Nguyen Heimbürger, +5 more
- 01 Mar 2020 - 
TL;DR: It is concluded that GIP actions may have implications for the development of cardiovascular disease, but also that the potential of GIP-based drugs for the treatment of cardiovascular Disease currently is uncertain.